Interesting facts
Interesting Facts about 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
This compound, renowned for its structural complexity, falls within the category of benzimidazole derivatives, which have garnered attention in various fields of medicinal chemistry. Here are some noteworthy aspects:
- Pharmacological Potential: Benzimidazole compounds are often investigated for their biological activities, including antifungal, anti-inflammatory, and anticancer properties. This specific compound has been studied for its potential use in treating certain types of diseases.
- Substituent Significance: The inclusion of a trifluoroethoxy group contributes to the compound’s unique characteristics, enhancing lipophilicity and biological activity. Fluorinated compounds can exhibit interesting pharmacokinetic properties, making them valuable in drug design.
- Mechanistic Insights: The presence of a methylsulfinyl moiety suggests that this compound might interact with various biological targets, potentially affecting metabolic pathways. Such functionalities are crucial for improving selectivity and potency against specific receptors.
- Synthesis Challenges: The synthesis of this compound may involve intricate multi-step processes due to its structural complexity. Each step must be carefully controlled to ensure the desired orientation and functionalization of the benzene ring and pyridine derivatives.
- Research Applications: The structural features of this compound make it an excellent candidate for further research in the development of novel therapeutic agents. Scientists are continuously exploring derivatives of benzimidazole that can provide solutions in fields ranging from oncology to infectious diseases.
As we explore the vast potential of compounds like this, we are reminded of the words of famous chemist Linus Pauling: "The best way to have a good idea is to have a lot of ideas." Innovations in medicinal chemistry often arise from understanding complex compounds and their interactions within biological systems.
Synonyms
lansoprazole
103577-45-3
Prevacid
Limpidex
Agopton
Lanzor
Bamalite
Lansoprazol
Monolitum
Takepron
Ogastro
Prevacid SoluTab
Lanzopral
Opiren
Zoton
Lanproton
Lansopep
Lasoprol
Mesactol
Aprazol
Blason
Ketian
Lancid
Lanston
Lanz
lanzoprazole
Lansoprazolum
Prosogan
Suprecid
Compraz
Ilsatec
Lansox
Zoprol
Dakar
Ogast
Promp
AG-1749
Prevacid Iv
PrevOnco
Lanzol-30
AG 1749
Prevacid 24HR
Prevacid I.V.
Ogastoro
A-65006
Lansoprazol [INN-Spanish]
Lansoprazolum [INN-Latin]
Lanzol
Lanzul
Lanzo
CHEBI:6375
HSDB 7204
UNII-0K5C5T2QPG
0K5C5T2QPG
MFCD00866873
NSC-758638
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
BRN 4333393
Prezal
A 65006
1261394-42-6
DTXSID4023200
Pro Ulco
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
R-(+)-LANSOPRAZOLE
TAK-390MR
(+/-)-LANSOPRAZOLE
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
MLS000069705
DTXCID703200
Lansoprazole [USAN:USP:INN:BAN]
PREVPAC COMPONENT LANSOPRAZOLE
1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
NSC 758638
NCGC00015615-02
SMR000058469
CAS-103577-45-3
Lansoprazol (INN-Spanish)
Lansoprazolum (INN-Latin)
MLS-0003247.0001
Prevacid NapraPAC
1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
LANSOPRAZOLE (MART.)
LANSOPRAZOLE [MART.]
LANSOPRAZOLE (USP-RS)
LANSOPRAZOLE [USP-RS]
TAK 390MR
Lansoprazoles
Lansophed
LANSOPRAZOLE (EP MONOGRAPH)
LANSOPRAZOLE [EP MONOGRAPH]
Lansoprazole (USAN:USP:INN:BAN)
LANSOPRAZOLE (USP MONOGRAPH)
LANSOPRAZOLE [USP MONOGRAPH]
2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
Prevacid (TN)
2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole
SR-01000000169
Lanfast
Lapraz
LansoprazoleDR
Lansoprazole DR
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole
ABT-006
equate lansoprazole
Lansoprazole,(S)
Lansoprazole24 HR
Prevacid 24 Hr
safeway acid reducer
Sunmark Lansoprazole
Topcare Lansoprazole
Equaline Lansoprazole
CG-4801
Dg Health Lansoprazole
Basic Care Lansoprazole
Good Sense Lansoprazole
Spectrum_001580
Up and Up Lansoprazole
caring mill lansoprazole
CPD000058469
Lansoprazole (Standard)
Health Mart Lansoprazole
Prevacid Delayed Release
Opera_ID_1676
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
LANSOPRAZOLE [MI]
Lopac-L-8533
Heartburn Relief 24 Hour
LANSOPRAZOLE [INN]
LANSOPRAZOLE [JAN]
CHEMBL480
L 8533
LANSOPRAZOLE [HSDB]
LANSOPRAZOLE [USAN]
lansoprazole delayed release
cid_3883
Signature Care Acid Reducer
LANSOPRAZOLE [VANDF]
Lopac0_000709
SCHEMBL22365
BSPBio_001084
BSPBio_001830
KBioGR_001491
KBioSS_002060
Lansoprazole impurity standard
MLS000759405
MLS001074170
MLS001424235
BIDD:GT0006
DivK1c_000920
LANSOPRAZOLE [WHO-DD]
SPECTRUM1503926
SPBio_000488
SPBio_002992
Kirkland Signature Lansoprazole
Berkley and Jensen Lansoprazole
BPBio1_001194
GTPL7208
BDBM47032
HMS502N22
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
Lansoprazole (JP17/USP/INN)
Lansoprazole - Bio-X trade mark
A02BC03
Levolansoprazole;(-)-Lansoprazole
MJIHNNLFOKEZEW-UHFFFAOYSA-O
NINDS_000920
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS2098G06
HMS2234B10
HMS3262M19
HMS3264E12
HMS3269D15
HMS3371E21
HMS3394F05
HMS3413J05
HMS3654J17
HMS3677J05
HMS3715G06
LANSOPRAZOLE [ORANGE BOOK]
Pharmakon1600-01503926
Pharmakon1600-01504282
Equate Lansoprazole Delayed Release
Good Neighbor Pharmacy Lansoprazole
BCP22331
BCP34129
Lansoprazole for peak identification
Tox21_110184
Tox21_301023
Tox21_500709
BBL029072
BDBM50070208
CCG-39952
HY-13662R
NSC758638
NSC758710
s1354
STK621169
AKOS005554811
Tox21_110184_1
AC-1233
CS-1847
DB00448
FM24839
KS-1075
Lansoprazole, >=98% (TLC), powder
LP00709
NC00411
SB19127
SDCCGSBI-0050687.P004
2-(2-benzimidazolylsulfinylmethyl)-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
IDI1_000920
LANSOPRAZOLE COMPONENT OF PREVPAC
NCGC00015615-01
NCGC00015615-03
NCGC00015615-04
NCGC00015615-05
NCGC00015615-06
NCGC00015615-07
NCGC00015615-08
NCGC00015615-09
NCGC00015615-10
NCGC00015615-11
NCGC00015615-12
NCGC00015615-14
NCGC00015615-15
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NCGC00254925-01
NCGC00261394-01
NCGC00381720-13
BL166173
HY-13662
SY052771
SBI-0050687.P003
AB00052388
EU-0100709
L0233
NS00000543
SW197226-4
D00355
F20528
Kirkland Signature Lansoprazole Delayed Release
AB00052388-17
AB00052388_18
AB00052388_19
Q254296
SR-01000000169-2
SR-01000000169-6
SR-01000000169-9
BRD-A49172652-001-05-7
BRD-A49172652-001-13-1
BRD-A49172652-001-26-3
BRD-A49172652-001-27-1
BRD-A49172652-001-28-9
F2173-0222
Z1501485356
Lansoprazole, British Pharmacopoeia (BP) Reference Standard
Lansoprazole, European Pharmacopoeia (EP) Reference Standard
Lansoprazole, United States Pharmacopeia (USP) Reference Standard
(+)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole
2-[[ [3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]-sulfinyl]1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]-methyl]sulfinyl]benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole
2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzimidazole
2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-benzimidazole
2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)pyridin-2-ylmethanesulfinyl]-benzimidazole
2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl-methanesulfinyl]-1H-benzimidazole
2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethanesulfinyl]-1H-benzimidazole
2-3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethylsulfinyl-1H-benzoimidazole
Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard
(RS)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-Benzimidazole
2-[[[3-METHYL-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDIN-2-YL]METHYL]SULFINYL]-1H-BENZO[D]IMIDAZOLE
Solubility of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
The solubility of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole (C17H19F3N3O3S) presents a complex profile due to its intricate molecular structure. Here are some insights into its solubility characteristics:
In summary, understanding the solubility behaviour of this compound is critical for its applications in pharmaceuticals and related fields. As with many compounds, it is essential to consider the solvent environment to fully appreciate its solubility properties.